The Institute for OneWorld Health Receives BMGF Grant to Combat Diarrheal Disease
Silencing a Global Health Challenge that Kills Two Million Children a Year.
1 November 2006-The Institute for OneWorld Health (San Francisco, CA) will receive a $46.07 million grant from the Bill and Melinda Gates Foundation (BMGF) to explore alternative cures for diarrheal disease. This is the largest grant the BMGF has ever awarded to an organization to address diarrheal disease, the overlooked global health challenge that kills more than two million children annually.
The grant is focused on identifying and developing new approaches to curing diarrheal disease, a chronic and pervasive killer whose bacterial sources are varied, but widespread in the developing world.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.
